Healthcare provider profile · identity verified

Jonathan Kang, D.O.

Family Practice · LOS ANGELES, CA · NPI 1659829380

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	464	194
Amlodipine Besylate	Amlodipine Besylate	174	76
Rosuvastatin Calcium	Rosuvastatin Calcium	163	67
Lisinopril	Lisinopril	158	65
Losartan Potassium	Losartan Potassium	156	68
Metformin Hcl	Metformin Hcl	147	62
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	125	51
Terazosin Hcl	Terazosin Hcl	96	44
Omeprazole	Omeprazole	90	49
Meloxicam	Meloxicam	87	53
Metformin Hcl Er	Metformin Hcl	87	40
Glipizide	Glipizide	86	42
Levothyroxine Sodium	Levothyroxine Sodium	80	34
Gabapentin	Gabapentin	72	39
Tamsulosin Hcl	Tamsulosin Hcl	71	30
Simvastatin	Simvastatin	68	24
Atenolol	Atenolol	64	26
Albuterol Sulfate Hfa	Albuterol Sulfate	61	31
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	60	60
Famotidine	Famotidine	60	29
Ibuprofen	Ibuprofen	60	37
Ozempic	Semaglutide	58	13
Furosemide	Furosemide	56	28
Alendronate Sodium	Alendronate Sodium	52	20
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	52	29
Glipizide-Metformin	Glipizide/Metformin Hcl	49	18
Tramadol Hcl	Tramadol Hcl	47	17
Hydrochlorothiazide	Hydrochlorothiazide	44	23
Jardiance	Empagliflozin	43	22
Fluticasone Propionate	Fluticasone Propionate	42	24
Lorazepam	Lorazepam	42	14
Pregabalin	Pregabalin	39	suppressed
Finasteride	Finasteride	38	18
Pantoprazole Sodium	Pantoprazole Sodium	37	15
Clobetasol Propionate	Clobetasol Propionate	36	11
Trazodone Hcl	Trazodone Hcl	36	24
Metoprolol Tartrate	Metoprolol Tartrate	34	12
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	31	17
Naproxen	Naproxen	31	22
Allopurinol	Allopurinol	30	17
Ciclopirox	Ciclopirox	29	16
Lovastatin	Lovastatin	29	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	28	26
Carvedilol	Carvedilol	27	12
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	27	16
Hydrocortisone	Hydrocortisone	27	17
Spironolactone	Spironolactone	27	13
Clopidogrel	Clopidogrel Bisulfate	26	12
Metoprolol Succinate	Metoprolol Succinate	26	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	26	13
Prednisone	Prednisone	26	22
Pioglitazone Hcl	Pioglitazone Hcl	24	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	23	suppressed
Sertraline Hcl	Sertraline Hcl	21	12
Humulin N Kwikpen	Insulin Nph Human Isophane	20	suppressed
Mupirocin	Mupirocin	20	16
Terbinafine Hcl	Terbinafine Hcl	20	18
Colchicine	Colchicine	19	suppressed
Glipizide Er	Glipizide	19	12
Humulin N	Insulin Nph Human Isophane	18	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	18	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	18	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	17	suppressed
Citalopram Hbr	Citalopram Hydrobromide	17	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	17	17
Zolpidem Tartrate	Zolpidem Tartrate	17	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	16	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	16	suppressed
Lactulose	Lactulose	16	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	16	suppressed
Metronidazole	Metronidazole	16	suppressed
Estradiol	Estradiol	15	suppressed
Mirtazapine	Mirtazapine	15	suppressed
Victoza 2-Pak	Liraglutide	15	suppressed
Ketoconazole	Ketoconazole	14	suppressed
Potassium Chloride	Potassium Chloride	14	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	13	12
Fluoxetine Hcl	Fluoxetine Hcl	13	suppressed
Ondansetron Odt	Ondansetron	13	suppressed
Donepezil Hcl	Donepezil Hcl	12	suppressed
Gavilyte-C	Peg3350/Sod Sulf,bicarb,cl/Kcl	12	12
Hydralazine Hcl	Hydralazine Hcl	12	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Buspirone Hcl	Buspirone Hcl	11	suppressed
Duloxetine Hcl	Duloxetine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error